NCT03193190 2025-11-21A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)Hoffmann-La RochePhase 1/2 Completed341 enrolled 28 charts
NCT02907099 2025-02-19Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic CancerM.D. Anderson Cancer CenterPhase 2 Completed20 enrolled 12 charts
NCT01838395 2024-09-19Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML PatientsBioLineRx, Ltd.Phase 2 Completed42 enrolled 19 charts
NCT03154827 2024-09-05Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)BioLineRx, Ltd.Phase 1/2 Terminated1 enrolled 6 charts
NCT02639559 2023-11-07Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesWashington University School of MedicinePhase 2 Completed50 enrolled 23 charts